215 related articles for article (PubMed ID: 25081318)
1. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation.
Yuan H; Cai P; Li Q; Wang W; Sun Y; Xu Q; Gu Y
Biomed Pharmacother; 2014 Jul; 68(6):751-6. PubMed ID: 25081318
[TBL] [Abstract][Full Text] [Related]
2. Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity.
Zhang X; Fang X; Gao Z; Chen W; Tao F; Cai P; Yuan H; Shu Y; Xu Q; Sun Y; Gu Y
Anticancer Drugs; 2014 Feb; 25(2):204-11. PubMed ID: 24135499
[TBL] [Abstract][Full Text] [Related]
3. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.
Ko JS; Rayman P; Ireland J; Swaidani S; Li G; Bunting KD; Rini B; Finke JH; Cohen PA
Cancer Res; 2010 May; 70(9):3526-36. PubMed ID: 20406969
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
5. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
6. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
[TBL] [Abstract][Full Text] [Related]
7. Axitinib in metastatic renal cell carcinoma.
Albiges L; Gizzi M; Carton E; Escudier B
Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
[TBL] [Abstract][Full Text] [Related]
8. The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
Heine A; Held SA; Daecke SN; Riethausen K; Kotthoff P; Flores C; Kurts C; Brossart P
PLoS One; 2015; 10(6):e0128897. PubMed ID: 26042424
[TBL] [Abstract][Full Text] [Related]
9. Axitinib in the treatment of metastatic renal cell carcinoma.
Ho TH; Jonasch E
Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
[TBL] [Abstract][Full Text] [Related]
10. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
Harada M; Iida Y; Kotani H; Minami T; Komohara Y; Eto M; Yoshikawa K; Uemura H
Cancer Immunol Immunother; 2022 Feb; 71(2):339-352. PubMed ID: 34160685
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Xin H; Zhang C; Herrmann A; Du Y; Figlin R; Yu H
Cancer Res; 2009 Mar; 69(6):2506-13. PubMed ID: 19244102
[TBL] [Abstract][Full Text] [Related]
12. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
13. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
Zakharia Y; Zakharia K; Rixe O
Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
[TBL] [Abstract][Full Text] [Related]
14. Axitinib for renal cell carcinoma.
Sonpavde G; Hutson TE; Rini BI
Expert Opin Investig Drugs; 2008 May; 17(5):741-8. PubMed ID: 18447599
[TBL] [Abstract][Full Text] [Related]
15. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
16. Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3.
Diao J; Yang X; Song X; Chen S; He Y; Wang Q; Chen G; Luo C; Wu X; Zhang Y
Med Oncol; 2015 Feb; 32(2):453. PubMed ID: 25603952
[TBL] [Abstract][Full Text] [Related]
17. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
Rössler J; Monnet Y; Farace F; Opolon P; Daudigeos-Dubus E; Bourredjem A; Vassal G; Geoerger B
Int J Cancer; 2011 Jun; 128(11):2748-58. PubMed ID: 20715103
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
19. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells.
Morelli MB; Amantini C; Santoni M; Soriani A; Nabissi M; Cardinali C; Santoni A; Santoni G
Oncotarget; 2015 Nov; 6(34):36245-59. PubMed ID: 26474283
[TBL] [Abstract][Full Text] [Related]
20. Corosolic acid impairs tumor development and lung metastasis by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells.
Horlad H; Fujiwara Y; Takemura K; Ohnishi K; Ikeda T; Tsukamoto H; Mizuta H; Nishimura Y; Takeya M; Komohara Y
Mol Nutr Food Res; 2013 Jun; 57(6):1046-54. PubMed ID: 23417831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
